share_log

Mangoceuticals | CORRESP: CORRESP

Mangoceuticals | CORRESP: CORRESP

Mangoceuticals | CORRESP:信函
美股SEC公告 ·  09/03 12:49

Moomoo AI 已提取核心信息

Mangoceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form S-1, initially filed on August 16, 2024. The company seeks to have the registration become effective at 4:30 p.m. EDT on September 5, 2024. This request was made under Rule 461 of the Securities Act of 1933, as amended. The correspondence, signed by Chairman and CEO Jacob D. Cohen, indicates Mangoceuticals' intention to move forward with its registration as soon as practicable.
Mangoceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form S-1, initially filed on August 16, 2024. The company seeks to have the registration become effective at 4:30 p.m. EDT on September 5, 2024. This request was made under Rule 461 of the Securities Act of 1933, as amended. The correspondence, signed by Chairman and CEO Jacob D. Cohen, indicates Mangoceuticals' intention to move forward with its registration as soon as practicable.
Mangoceuticals公司正式请求美国证券交易委员会(SEC)加快其于2024年8月16日首次提交的S-1表格的注册声明的生效。该公司希望注册在2024年9月5日下午4:30生效。这一请求是根据1933年证券法修正案第461条规定提出的。由董事长兼首席执行官Jacob D. Cohen签署的函件表明了Mangoceuticals打算尽快推进注册的意图。
Mangoceuticals公司正式请求美国证券交易委员会(SEC)加快其于2024年8月16日首次提交的S-1表格的注册声明的生效。该公司希望注册在2024年9月5日下午4:30生效。这一请求是根据1933年证券法修正案第461条规定提出的。由董事长兼首席执行官Jacob D. Cohen签署的函件表明了Mangoceuticals打算尽快推进注册的意图。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息